(LOOTPRESS) – The Drug Enforcement Administration has introduced a sweeping new proposed rule that would significantly expand the ability of medical providers to prescribe Schedule III–V controlled substances through telemedicine. If finalized, the proposal would mark a major shift in federal policy and a permanent acknowledgment that telehealth is now embedded in modern medical practice.
But what may be most noteworthy for West Virginia is this: the federal rule mirrors — and in many ways validates — the telehealth expansions West Virginia has already enacted at the state level over the past several years.
At a time when rural health access, opioid-era regulation, and provider shortages dominate our policy conversations, the alignment between federal and state directions is striking.
What the DEA’s New “Special Registration” Rule Would Do
The DEA’s proposal creates a new pathway allowing practitioners to prescribe certain controlled substances via telemedicine without a prior in-person exam. Highlights include:
1. Mandatory Audio-Video Telehealth Visits
Prescribing Schedule III–V controlled substances would require a real-time audiovisual telehealth examination. A narrow audio-only exception exists for patients who cannot access video.
2. Cross-State Licensing Requirements
Providers must still comply with the licensing and telemedicine rules of the state where the patient is located — something very relevant for West Virginia, where many patients rely on out-of-state specialists.
3. Required PDMP Checks
Before prescribing, clinicians must check the Prescription Drug Monitoring Program (PDMP) for the patient’s state, mirroring West Virginia’s own Controlled Substance Monitoring Program (CSMP) requirements.
4. Schedule II Limitations Remain
No remote prescribing of Schedule II medications (opioids, stimulants, etc.) unless an in-person relationship already exists. That framework closely mirrors existing West Virginia restrictions.
How West Virginia Has Already Prepared for This Moment
Over the past several years, while federal policy stalled or reacted inconsistently, West Virginia has steadily modernized and expanded its telehealth laws. In fact, in many respects, state laws anticipated the federal telemedicine reforms the DEA is now proposing.
West Virginia Code § 30-1-26 – The Foundation of State Telehealth Expansion
West Virginia’s comprehensive telehealth statute recognizes telemedicine as a full and legitimate practice of medicine. Key provisions include:
When the law was updated, it was widely viewed as one of the most forward-leaning telemedicine frameworks in rural America. At a time when provider access in the Mountain State was stressed to the limit, the expansions of telehealth created by the legislature between 2020 through the present have been used as a model for telehealth expansion in rural communities across the United States. West Virginia’s advances have providedcritical services to areas in desperate need of qualified providers.
Telemedicine Prescribing Rules for Controlled Substances
West Virginia’s legislative rules for physicians and advanced practice nurses (e.g., W.Va. C.S.R. §§ 24-10-8 and 19-16-8) add important detail:
In other words, West Virginia has already built a hybrid model: expand access but increase oversight.
Medicaid and Insurance Policy Changes Pushed Telehealth Forward Even Faster
West Virginia Medicaid updated its telehealth policy to explicitly encourage telemedicine across a wide range of specialties. Importantly:
These policies were adopted at a time when federal agencies hesitated or issued temporary waivers. West Virginia moved first.
Where the Federal DEA Rule and WV Law Now Align
The DEA’s proposed telemedicine rule does not conflict with West Virginia’s direction — it validates it.
Both frameworks:
The DEA’s proposal effectively mirrors the policy architecture West Virginia adopted years earlier.
Where Conflict May Still Exist
Despite the broad alignment, several potential gaps remain:
1. West Virginia’s Schedule II Restrictions Are Stricter Than Federal Allowances
Even if the DEA permits limited remote Schedule II prescribing under special registration, West Virginia law still prohibits it without pre-existing in-person care.
Federal permission doesn’t override state law.
2. Provider Burden: Licensing and Registration
The DEA rule makes federal prescribing easier, but West Virginia’s requirement that out-of-state telehealth providers register with state boards may still pose barriers.
3. Medicaid Reimbursement Limitations
Some categories of telehealth care may still face reimbursement bottlenecks that federal policy cannot fix.
What This Means for West Virginia Patients and Providers
For Patients
This alignment is especially important in a rural state. Telehealth has already proven its value for:
The DEA’s rule will likely increase the number of available providers — including specialists outside West Virginia — especially for Schedule III–V therapies.
For Providers
Clinicians will still need to:
But the bigger picture is positive: the federal government is finally supporting the direction West Virginia set years ago.
For Future Manufacturing, Compounding, and Dispensing Trends
As telehealth prescribing becomes standard, supply-chain and dispensing models will shift.
A trade group — such as the peptide and advanced-therapeutics association you are developing — could play a major role in influencing:
West Virginia’s early adoption of telehealth positions the state as a policy leader in these areas.
While much of the country is only now seeing federal movement on telemedicine prescribing, West Virginia’s Legislature and regulatory agencies were ahead of the curve.
The DEA’s newly proposed “special registration” rule fits cleanly into a telehealth framework our state already built.
For rural communities, working families, addiction-recovery patients, and those seeking specialized care, this alignment could ultimately expand access while keeping appropriate safeguards in place.
